Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

被引：1

作者：

Boissard, Frederic ^{[1
]}

Tilly, Herve ^{[2
,3
,4
]}

Lenz, Georg ^{[5
]}

Collins, Graham P. ^{[6
]}

Pinto, Antonio ^{[7
]}

Sehn, Laurie H. ^{[8
,9
]}

Salles, Gilles ^{[10
]}

Roussel, Mathilde ^{[1
]}

Simonella, Leonardo ^{[1
]}

Ho, Rodrigo ^{[1
]}

Hirata, Jamie ^{[11
]}

Lee, Calvin ^{[11
]}

Masaquel, Anthony ^{[11
]}

Launonen, Aino ^{[1
]}

机构：

[1] F Hoffmann La Roche Ltd, Basel, Switzerland

[2] Ctr Henri Becquerel, Dept Hematol, Rouen, France

[3] Ctr Henri Becquerel, U1245, Rouen, France

[4] Univ Rouen, Rouen, France

[5] Univ Hosp Munster, Munster, Germany

[6] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England

[7] Fdn G Pascale, IRCCS, Natl Canc Inst, Naples, Italy

[8] Ctr Lymphoid Canc BC Canc, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Genentech Inc, San Francisco, CA 94080 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157904

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6645 / 6647

页数：3

共 50 条

[1] Epidemiological impact of Polatuzumab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) use in previously untreated Diffuse Large B-cell Lymphoma (DLBCL) on Second Line (2L) treatment: an ad hoc analysis from POLARIX study
Oellerich, T.
Boissard, F.
Tilly, H.
Lenz, G.
Collins, G. P.
Pinto, A.
Sehn, L. H.
Salles, G.
Roussel, M.
Simonella, L.
Ho, R.
Hirata, J.
Lee, C.
Masaquel, A.
Launonen, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 267 - 267
[2] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
Tilly, H.
Sharman, J.
Bartlett, N.
Morschhauser, F.
Haioun, C.
Munoz, J.
Chen, A.
Lamy, T.
Wang, L.
Penuel, E.
Hirata, J.
Lee, C.
Salles, G.
HAEMATOLOGICA, 2017, 102 : 4 - 4
[3] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta Costa, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher R.
Salles, Gilles
BLOOD, 2021, 138
[4] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
Dietrich, S.
Tilly, H.
Morschhauser, F.
Sehn, L. H.
Friedberg, J.
Trneny, M.
Sharman, J. P.
Herbaux, C.
Burke, J. M.
Matasar, M.
Rai, S.
Izutsu, K.
Mehta-Shah, N.
Oberic, L.
Chauchet, A.
Jurczak, W.
Song, Y.
Greil, R.
Mykhalska, L.
Burgues, J. M. B.
Cheung, M. C.
Pinto, A.
Shin, H-J
Hapgood, G.
Munhoz, E.
Abrisqueta, P.
Gau, J-P
Hirata, J.
Jiang, Y.
Yan, M.
Lee, C.
Flowers, C.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
[5] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Flowers, Christopher
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
[6] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
Dietrich, Sascha
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yu Qin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Salles, Gilles
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
[7] Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Miguel, Juan
Burgues, Bergua
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher
Salles, Gilles
Collins, Graham
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 14 - 16
[8] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[9] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Friedberg, Jonathan W.
Thompson, Carrie A.
Trneny, Marek
Morschhauser, Franck
Salles, Gilles
Reagan, Patrick M.
Hertzberg, Mark
Smolewski, Piotr
Zhang, Huilai
Thieblemont, Catherine
Hu, Bei
Fonseca, Gustavo
Kim, Won-Seog
Martelli, Maurizio
Mehta, Amitkumar
Campinha-Bacote, Avrita
Yan, Mark
Hirata, Jamie
Sugidono, Matthew
Lee, Calvin
Sharman, Jeff P.
BLOOD, 2022, 140 : 6623 - 6626
[10] Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone ( Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Miyao, Kotaro
Wakayama, Tomoyoshi
Ozaki, Somi
Numata, Masaya
Negishi, Shuto
Ohara, Fumiya
Motegi, Kenta
Wakabayashi, Hiroya
Sawa, Hitomi
Sakai, Toshiyasu
Inagaki, Yuichiro
Sawa, Masashi
BLOOD, 2023, 142

← 1 2 3 4 5 →